IOBENGUANE I-123 (iobenguane sulfate i-123) · BWXT MEDCL
IOBENGUANE I-123 is FDA-approved to treat 3 conditions (same as ADREVIEW).
Details
- Status
- Discontinued
- First Approved
- 2024-12-09
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
IOBENGUANE I-123 Approval History
What IOBENGUANE I-123 Treats
3 indicationsIOBENGUANE I-123 is approved for 3 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Pheochromocytoma
- Neuroblastoma
- Heart Failure
Same approved indications as ADREVIEW (same active ingredient).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
IOBENGUANE I-123 FDA Label Details
Indications & Usage
IOBENGUANE I-123 is FDA-approved to treat 3 conditions — same approved indications as ADREVIEW.
Looking for the branded version?
ADREVIEW
Full clinical data, patents, trials, and competitive landscape for iobenguane sulfate i-123.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.